Bitopertin
investig.
Pronunciation: bye-toe-PER-tin
What it isGlycine transporter type 1 inhibitor; failed in schizophrenia, now studied in erythropoietic protoporphyria.
Why this oneRaising synaptic glycine was the leading strategy for NMDA hypofunction in schizophrenia.
What limits itFailed phase 3 schizophrenia program reframed the glycine hypothesis. Investigational only.
Used for
- schizophrenia (failed trials) / erythropoietic protoporphyria (investigational)
- erythropoietic protoporphyria (phase 3)
- schizophrenia (failed phase 3)
NO BOXED WARNINGS
Principal riskThe schizophrenia program failed in phase 3
Classes and tags
Clinical profile
Open Bitopertin in the interactive console ↗
Self-check
- What happened to bitopertin’s phase 3 schizophrenia program?
It failed. - Which newer disease is bitopertin being studied in?
Erythropoietic protoporphyria.